Form 4: 4D Molecular Therapeutics Chief Legal Officer Exercises Options and Sells Shares

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, executed stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Summary

• On September 16, 2024, Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options to acquire 500 shares of common stock at a price of $6.49 per share.
• Simultaneously, Bizily sold 500 shares of common stock at a price of $16.33 per share.
• These transactions were executed under a 10b5-1 trading plan adopted on October 10, 2023.
• Following these transactions, Bizily directly owns 6,781 shares of 4D Molecular Therapeutics common stock and holds options for 10,379 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports insider trading activity under a pre-arranged plan. There is no indication of positive or negative implications for the company.

Future Outlook

The filing does not contain any forward-looking statements regarding the company's future performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is important for investors to monitor.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the small number of shares involved.

Key Dates